Abstract
Mucociliary clearance (MCC) is an innate defense mechanism that normally keeps airways clean but is dysfunctional in cystic fibrosis (CF) and other muco-obstructive pulmonary diseases. Previously we discovered that activating adenyl cyclase in combination with a cholinergic agonist increased MCC velocity (MCCV) synergistically in ex vivo WT and CF ferret and WT piglets. For what we believe is the first time, we show in vivo synergistic MCC using FDA approved β-adrenergic and cholinergic drugs delivered to the apical surface of WT and CF rats and a CF sheep model. Also, a single dose of the combined drugs is tolerated by humans. As for mechanisms, via ex vivo experiments, we show the combined agonists increased net fluid secretion mainly by stimulating gland secretion and by inhibiting surface absorption, consequently increasing airway surface liquid depth. They also increased net base secretion and increased ciliary beat frequency. Additional ex vivo and in vitro experiments show that the combined agonists had additive effects when combined with highly effective CF transmembrane conductance regulator modulator therapy. The synergistic increase in MCCV induced by this combination of agonists offers therapeutic potential for treating muco-obstructive pulmonary diseases, including CF.
Funding Information
  • Stanford University (IMA-1070,Joo19Go,MILLA23G0,Cystic Fibrosis Research Inc.,the Ross Mosier CF Research Laboratories gift fund,)
  • Stanford University (the Galper Family CF fund)
  • University of Iowa (R01 HL165404,NHLBI Federal Contract 75N92025C00007)
  • Center for AIDS Research, Heersink School of Medicine, University of Alabama at Birmingham (CFF BIRKET23XX0)

This publication has 54 references indexed in Scilit: